share_log

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144：擬議出售證券
美股SEC公告 ·  08/07 04:54
牛牛AI助理已提取核心訊息
Recursion Pharmaceuticals, Inc. Director Borgeson Blake is set to sell 11,447 Class A shares of the company on 08/06/2024, as per the latest filing. These shares, valued at approximately $78,083.44, were originally acquired on 09/01/2016 as founders shares and as part of compensation from the issuer. This planned sale follows a series of transactions over the past three months, where a total of 77,289 shares were sold for gross proceeds of $694,221.07.
Recursion Pharmaceuticals, Inc. Director Borgeson Blake is set to sell 11,447 Class A shares of the company on 08/06/2024, as per the latest filing. These shares, valued at approximately $78,083.44, were originally acquired on 09/01/2016 as founders shares and as part of compensation from the issuer. This planned sale follows a series of transactions over the past three months, where a total of 77,289 shares were sold for gross proceeds of $694,221.07.
最新提交的文件顯示，Recursion Pharmaceuticals, Inc.的董事Borgeson Blake計劃於2024年08月06日出售11,447股A類股份。這些股份價值約爲78,083.44美元，最初於2016年09月01日作爲創始人股份和發行人的報酬獲得。這項計劃中的銷售是近三個月以來一系列交易的後續，共銷售了77,289股，總收入爲694,221.07美元。
最新提交的文件顯示，Recursion Pharmaceuticals, Inc.的董事Borgeson Blake計劃於2024年08月06日出售11,447股A類股份。這些股份價值約爲78,083.44美元，最初於2016年09月01日作爲創始人股份和發行人的報酬獲得。這項計劃中的銷售是近三個月以來一系列交易的後續，共銷售了77,289股，總收入爲694,221.07美元。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。